What is chronic inactive gastritis and what treatment is recommended?

What is Chronic Inactive Gastritis?

Chronic inactive gastritis is a histopathologic pattern characterized by chronic inflammation (lymphocytes and plasma cells) in the gastric mucosa WITHOUT active neutrophilic inflammation, most commonly representing either a post-treatment state after H. pylori eradication or proton pump inhibitor (PPI) therapy, or a stage in the progression toward atrophic gastritis.

Definition and Clinical Context

Chronic inactive gastritis represents a distinct histopathologic finding where:

• Mononuclear inflammatory cells (lymphocytes, plasma cells) infiltrate the gastric mucosa
• Active inflammation (neutrophils) is absent
• It may occur with or without glandular loss (atrophy)

The term "inactive" specifically refers to the absence of neutrophilic activity, not the absence of disease progression risk 1.

Key Clinical Scenarios

Most commonly, chronic inactive gastritis indicates:

1. Post-H. pylori eradication state - The bacteria have been treated but chronic inflammation persists 1, 2
2. PPI therapy effect - Acid suppression can convert active gastritis to an inactive pattern 1
3. Early/minimal atrophic gastritis - May represent pre-existing H. pylori gastritis progressing toward atrophy 2

In one study, 56% of patients with chronic inactive gastritis had recent PPI or H. pylori eradication therapy, and 50% showed evidence of prior H. pylori infection by serology 1, 2.

Recommended Treatment Approach

Step 1: Assess for H. pylori Status

All patients with chronic inactive gastritis must be tested for H. pylori infection 3. This is critical because:

• If H. pylori positive: Treat with appropriate eradication therapy and confirm successful eradication with non-serological testing (stool antigen or urea breath test, NOT serology) 3
• If H. pylori negative: Determine if prior infection/eradication occurred through medication history and consider serologic testing 1, 2

Important caveat: Modified Giemsa stain may miss coccoid forms of H. pylori in patients on PPIs or recent eradication therapy 1. If clinical suspicion is high despite negative histology, use non-invasive testing.

Step 2: Determine if Atrophy is Present

Chronic inactive gastritis may represent atrophic gastritis, which fundamentally changes management 3:

• Atrophic gastritis is defined as loss of gastric glands with or without metaplasia in the setting of chronic inflammation 3
• Requires histopathologic confirmation with biopsies from body and antrum in separate jars 3
• If intestinal metaplasia is present, atrophic gastritis is essentially confirmed 3

Step 3: Risk Stratification and Surveillance

For chronic inactive gastritis WITHOUT significant atrophy:

• No specific pharmacologic treatment is indicated beyond H. pylori eradication if positive
• Surveillance endoscopy is not routinely required
• Address symptoms with acid suppression if needed (PPIs, H2RAs, or P-CABs) 4

For chronic inactive gastritis WITH atrophic gastritis:

• Surveillance endoscopy every 3 years for advanced atrophic gastritis (extensive anatomic distribution or high-grade histology) 3
• Screen for nutritional deficiencies: vitamin B12 and iron, especially if corpus-predominant 3
• If autoimmune etiology suspected: check antiparietal cell antibodies, anti-intrinsic factor antibodies 3
• Screen for type 1 gastric neuroendocrine tumors in autoimmune gastritis 3

Step 4: Pharmacologic Management

No specific medication reverses chronic inactive gastritis, but treatment focuses on:

1. H. pylori eradication (if positive) - This is the only intervention that may prevent progression 3

2. Symptom management (if dyspeptic symptoms present):

   • Mucoprotective agents (promote mucosal regeneration, reduce inflammation) 4
   • H2-receptor antagonists for acid suppression 4
   • PPIs or P-CABs for robust acid control 4

3. Nutritional supplementation:

   • Vitamin B12 replacement if deficient (especially corpus-predominant disease) 3
   • Iron supplementation if deficient 3

Critical Pitfalls to Avoid

• Do not rely solely on histology for H. pylori detection in patients on PPIs or post-eradication - use stool antigen or breath testing 1
• Do not assume "inactive" means "benign" - this may represent evolving atrophic gastritis with cancer risk 3, 2
• Do not use serology alone to confirm eradication - antibodies persist after successful treatment 3
• Do not miss autoimmune gastritis - check for corpus-predominant atrophy and associated autoimmune conditions (thyroid disease) 3

Practical Algorithm Summary

Chronic Inactive Gastritis Diagnosed
         ↓
Test for H. pylori (histology + non-invasive if on PPIs)
         ↓
    ┌────┴────┐
Positive    Negative
    ↓           ↓
Eradicate   Check history/serology
Confirm     for prior infection
    ↓           ↓
Assess for atrophy (body + antrum biopsies)
         ↓
    ┌────┴────┐
No atrophy   Atrophy present
    ↓           ↓
Symptom     Surveillance q3 years
management  + nutritional screening
only        + autoimmune workup